New treatments for sepsis using peptide immunomodulators
Novel Peptide Immunomodulators for Treating Sepsis
This study is exploring new treatments for sepsis, a serious condition caused by infections, by using special proteins to help calm down the body's extreme inflammation and boost the immune system, with hopes of eventually helping patients like you.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eldec Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project ID | NIH-10602761 on NIH RePORTER |
What this research studies
This research focuses on developing novel peptide immunomodulators to treat sepsis, a severe condition caused by the body's extreme response to infection. The approach involves targeting a specific protein, Orai1, which plays a key role in the inflammatory response. By using peptidomimetics derived from a naturally occurring protein, the research aims to reduce inflammation and improve immune function in patients suffering from sepsis. The study will utilize animal models to evaluate the efficacy of these new treatments before considering clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing sepsis or severe systemic inflammation.
Not a fit: Patients with sepsis who are under 21 years old or those with other underlying conditions that complicate treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for sepsis patients.
How similar studies have performed: While the approach of using peptide immunomodulators is innovative, similar strategies targeting inflammatory pathways have shown promise in other conditions, indicating potential for success.
Where this research is happening
Durham, UNITED STATES
- Eldec Pharmaceuticals, INC. — Durham, United States (Active)
Researchers
- Principal investigator: Ahmad, Saira — Eldec Pharmaceuticals, INC.
- Study coordinator: Ahmad, Saira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.